Patents for A61P 35 - Antineoplastic agents (221,099)
08/2011
08/04/2011WO2011093465A1 Transformation plasmid
08/04/2011WO2011093365A1 Nitrogenated heterocyclic compound
08/04/2011WO2011093097A1 Anti-dll3 antibody
08/04/2011WO2011092840A1 Method for manufacturing polymethoxyflavones that are highly stable over time and have reduced residual pesticide levels
08/04/2011WO2011092675A2 Molecular complex for targeting antigens towards cells comprising antigens and uses thereof for vaccination
08/04/2011WO2011092505A1 S100 protein binding interaction inhibitors
08/04/2011WO2011092469A1 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
08/04/2011WO2011092295A2 Novel radioimmunoconjugates and uses thereof
08/04/2011WO2011092273A1 Treatment of gist with masitinib
08/04/2011WO2011092198A1 5-alkynyl-pyrimidines
08/04/2011WO2011092197A1 5-alkynyl pyrimidines and their use as kinase inhibitors
08/04/2011WO2011092120A1 6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators
08/04/2011WO2011092088A1 Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
08/04/2011WO2011091973A1 5-nitro-8-hydroxyquinolines as inhibitors of cathepsin b
08/04/2011WO2011091778A1 Production and use of antibacterial, antiproliferative, and antiphytopathogenic benzanthracenes
08/04/2011WO2011091719A1 Crystalline hydrates of alkyl acyl acetaldehyde sulfite, preparation methods and uses thereof
08/04/2011WO2011091716A1 Epidermal growth factor receptor variant
08/04/2011WO2011067356A3 Polymorphs of a mek inhibitor
08/04/2011WO2011067348A3 Mek inhibitor salts and solvates thereof
08/04/2011WO2011041729A3 Compounds as lysophosphatidic acid receptor antagonists
08/04/2011WO2011041613A3 Combination immunotherapy for the treatment of cancer
08/04/2011WO2011035143A3 Methods and compositions for inhibiting rho-mediated diseases and conditions
08/04/2011WO2011032000A9 Method for protection of antimicrobial and anticancer drugs from inactivation by nitric oxide
08/04/2011WO2011031073A3 Novel tetra-aza macrocyclic compound, method for preparing same, and use thereof
08/04/2011WO2011028947A3 Heterocyclic compounds for the inhibition of pask
08/04/2011US20110191872 Method for the humanization of antibodies and humanized antibodies thereby obtained
08/04/2011US20110191868 Methods for identification and use of agents targeting cancer stem cells
08/04/2011US20110191865 Novel Gene Disruptions, Compositions and Methods Relating Thereto
08/04/2011US20110190623 Thermally-activatable liposome compositions and methods for imaging, diagnosis and therapy
08/04/2011US20110190400 Novel Compounds for Treatment of Malignant Tumors
08/04/2011US20110190399 Curcumin nanoparticles and methods of producing the same
08/04/2011US20110190391 Ferrocene derivatives with anticancer activity
08/04/2011US20110190390 Methods and materials for treating pancreatic cancer
08/04/2011US20110190388 Ursolic acid derivative and pharmaceutical composition thereof
08/04/2011US20110190386 Aptamer Inhibitors of Osteopontin and Methods of Use Thereof
08/04/2011US20110190384 siRNA Specific to WT1 17AA(-)Isoform and Use Thereof
08/04/2011US20110190382 Treatment of Cancer by Inhibition of IGFBPs and Clusterin
08/04/2011US20110190380 Methods for delivery of sirna to bone marrow cells and uses thereof
08/04/2011US20110190375 Compositions comprising cmyc sirna and methods of use thereof
08/04/2011US20110190374 Methods of treating a meiotic kinesin associated disease
08/04/2011US20110190370 Modulation of hif1(alpha) and hif2(alpha) expression
08/04/2011US20110190368 Organosulfur Compounds, a Method of Making Organosulfur Compounds and their Use for Inhibiting the Growth of Tumour Cells
08/04/2011US20110190366 Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
08/04/2011US20110190363 Liquid formulations of bendamustine
08/04/2011US20110190355 Heterocyclic indazole derivatives
08/04/2011US20110190342 Glycine b antagonist
08/04/2011US20110190341 Substituted isoquinolines and isoquinolinones as rho kinase inhibitors
08/04/2011US20110190340 Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives
08/04/2011US20110190339 6-substituted isoquinolines and isoquinolinones
08/04/2011US20110190337 Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use
08/04/2011US20110190334 Heterocyclic Sulfonamide Derivatives
08/04/2011US20110190328 Acid addition salts of (3,5-bis trifluoromethyl)-n-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
08/04/2011US20110190326 Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
08/04/2011US20110190325 Compounds, their syntheses, and thier uses
08/04/2011US20110190323 Cortistatin analogues and syntheses thereof
08/04/2011US20110190321 Predictive marker for egfr inhibitor treatment
08/04/2011US20110190319 Substituted heteroaryl fused derivatives as pi3k inhibitors
08/04/2011US20110190318 Pharmaceutical dosage form for immediate release of an indolinone derivative
08/04/2011US20110190315 Indoline scaffold shp-2 inhibitors and cancer treatment method
08/04/2011US20110190312 Combinations Comprising Epothilones and Protein Tyrosine Kinase Inhibitors and Pharmaceutical Uses Thereof
08/04/2011US20110190311 Use of cdk inhibitor for the treatment of glioma
08/04/2011US20110190310 Hypoxia Activated Drugs Of Nitrogen Mustard Alkylators
08/04/2011US20110190308 Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
08/04/2011US20110190306 Inhibitors of PLK
08/04/2011US20110190305 Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same
08/04/2011US20110190304 Disubstituted phthalazine hedgehog pathway antagonists
08/04/2011US20110190302 Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use
08/04/2011US20110190297 Pyridine and pyrimidine based compounds as wnt signaling pathway inhibitors for the treatment of cancer
08/04/2011US20110190295 Compositions and methods for inhibition of hepatocyte growth factor receptor c-met signaling
08/04/2011US20110190294 Novel estrogen receptor ligands
08/04/2011US20110190293 Quinazolinone Compounds as Anticancer Agents
08/04/2011US20110190290 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
08/04/2011US20110190289 Imidazolothiadiazoles for Use as Protein Kinase Inhibitors
08/04/2011US20110190288 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) for use in treatment of diseases associated with a pten deficiency
08/04/2011US20110190282 Novel vegf-2 receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof
08/04/2011US20110190281 Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
08/04/2011US20110190280 Thiazole And Oxazole Kinase Inhibitors
08/04/2011US20110190275 C2-fluoro substituted piperazine linked pyrrolo[2,1-c][1,4] benzodiazepine dimers and a process for the preparation thereof
08/04/2011US20110190272 Chemical compounds
08/04/2011US20110190271 2,4-Pyrimidinediamine Compounds and Uses as Anti-Proliferative Agents
08/04/2011US20110190268 Novel Benzimidazole Linked Pyrrolo[2,1-c[1,4] Benzodiazepine Hybrids as Potential Antitumour Agents and Process for the Preparation Thereof
08/04/2011US20110190266 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
08/04/2011US20110190264 Compounds and compositions as kinase inhibitors
08/04/2011US20110190261 MAPK/ERK Kinase Inhibitors
08/04/2011US20110190258 Aryl benzylamine compounds
08/04/2011US20110190257 Bicyclic heterocycles as mek kinase inhibitors
08/04/2011US20110190256 Amine and Ether Compounds Which Modulate The CB2 Receptor
08/04/2011US20110190248 Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
08/04/2011US20110190246 Estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring
08/04/2011US20110190240 Nuclear factor kappa b pathway inhibitor composition and use of same
08/04/2011US20110190239 Bmi-1 protein expression modulators
08/04/2011US20110190237 Macrocyclic Prodrug Compounds Useful as Therapeutics
08/04/2011US20110190233 Anionic conjugates of glycosylated bacterial metabolite
08/04/2011US20110190227 Antagonists of Prostaglandin D2 Receptors
08/04/2011US20110190219 Treating cancer with granulocyte-macrophage colony stimulating factor
08/04/2011US20110190218 Bag-1 peptide that inhibits prostate cancer
08/04/2011US20110190204 Taxane- and Taxoid-Protein Compositions
08/04/2011US20110190203 Ophthalmic Compositions Containing A Synergistic Combination Of Two Polymers
08/04/2011US20110190202 Prevention of Cellular Senescence in Mammals by Natural Peptide Complexes
08/04/2011US20110190195 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress